Robert Chess is listed as a director on 8 SEC Form D filings by 3 issuers between Apr 2018 and Jun 2026: NEKTAR THERAPEUTICS (San Francisco, CA — pharmaceuticals — 2018–2024; $850M reported sold to 1 investors), BigHat Biosciences, Inc. (San Mateo, CA — biotechnology — 2022–2025; $124.1M reported sold to 40 investors) and Issio Solutions, Inc. (Lafayette, CA — other technology — 2023–2026; $3.97M reported sold to 48 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as director, over about 8 years. Across those companies the filings report $978.1M sold in total.
Listed alongside Arne Brock-Utne (4 shared filings), Mark Musco (4 shared filings), Yorick Phoenix (4 shared filings), Francisco Gimenez (2 shared filings), Howard W. Robin (2 shared filings) and 20 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 3 bankruptcy cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 8 public filings for Robert Chess and found 10 differences, 1 worth asking the sponsor about: Form D filed 95 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.